title: [The efficacy of p16, p53 and p21 genes on the proliferation of lung cancer cells in vitro].
abstract: OBJECTIVE
  Whether the p16, p21 and p53 genes inhibit the proliferation of lung cancer cells after transfecting the genes alone or jointly was examined.
  
  
  METHODS
  The p16, p21 and p53 genes mediated by Stearylamine/DOPE (SA liposome) were introduced alone and jointly into the non-small cell lung cancer (NSCLC) cell line A549 and small cell lung cancer (SCLC) SH77. The effect of the genes on the growth of the cells was detected by MTT method at day 1, 3, 5 after gene transfection.
  
  
  RESULTS
  The p16, p53 and p21 genes alone mediated by SA liposome can inhibit obviously the growth of NSCLC cell line A549 cells, while the genes were slightly effective on SCLC cell line SH77 cells at day 1, 3, 5 after transfecting the genes. But co-transfecting p16 and p21 or p16 and p53 can enhance the inhibiting effect on both A549 and SH77 cells significantly.
  
  
  CONCLUSIONS
  The tumor suppressor genes p16, p53 genes and CDK inhibitor p21 gene may be candidate for gene replacement therapy of NSCLC. Co-transfecting p16 gene and p53 gene may be a better choice.
authors.affiliation: Molecular Medical Center, Second Affiliated Hospital, JiangXi Medical college, Nanchang, 330006.
authors.forename: G
authors.initials: G
authors.lastname: Wen
authors.forename: J
authors.initials: J
authors.lastname: Li
authors.forename: G
authors.initials: G
authors.lastname: Zou
authors.forename: X
authors.initials: X
authors.lastname: Fan
authors.forename: W
authors.initials: W
authors.lastname: Rao
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000473:pathology / Q000628:therapy; D018288:Carcinoma, Small Cell / Q000235:genetics / Q000473:pathology / Q000628:therapy; D002455:Cell Division; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000235:genetics*; D019942:Genes, p16; D016158:Genes, p53; D015316:Genetic Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D014407:Tumor Cells, Cultured
chemical_list: C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins